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xpectations are high that pharmacogenomics (PGx) research will soon 
enable physicians to use genetic profiles to identify the safest and most 
effective treatments for each individual patient. Recent articles have 
addressed a range of important ethical considerations in translating emerging 
PGx research into clinical practice (Buchanan et al., 2002; Robertson et al., 2002; 
Clayton, 2003; van Delden et al., 2004; Corrigan, 2005; Lee, 2005; Ossorio and 
Duster, 2005; Roden et al., 2006; Marx-Stolting, 2007; Fitzgerald, 2008; Haga 
and Burke, 2008; Peterson-Iyer, 2008; Fleeman and Dickson, 2009), and a few 
have addressed issues related to PGx treatment strategies for addiction specifically 
(Shields et al., 2004; Caron et al., 2005; Munafo et al., 2005; Shields and Lerman, 
2008). Largely missing from these analyses has been consideration of distributive 
justice and health disparities.
Although eliminating health disparities is one of two primary goals of Healthy 
People 2010 (U.S. Department of Health and Human Services, 2000), the sub-
stance abuse field has made far more progress in documenting disparities than in 
reducing them (Fiscella et al., 2000; Hargraves et al., 2001; Kressin and Petersen, 
2001; Fiscella et al., 2002; Institute of Medicine, 2002a; 2002b; Schneider et al., 
2002; Saha et al., 2003). Compared with whites, racial and ethnic minorities have 
a greater need for substance abuse treatment (National Institute on Drug Abuse, 
2003) and are less likely to have access to it (Wells et al., 2001). The “treatment 
gap,” defined as the proportion of a population who are in need of drug or alcohol 
treatment but have not received any in the past year, increased for all nonwhite 
racial/ethnic groups between 2002 and 2009, with the exception of Asian Ameri-
cans (Schmidt and Mulia, 2009). 
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In this paper, I review major ethical issues pertinent 
to PGx research and its translation into practice, focus-
ing on the context of addiction. Reflecting concerns for 
distributive justice, I pay particular attention to ways 
in which PGx research and treatment strategies may 
exacerbate disparities in the burden of addiction.  Powers 
and Faden (2006) argue that individuals and groups who 
have been “systematically disadvantaged” by our health 
care system have a particular claim on public resources 
and investments.
Following the overview of major issues, I focus on 
two areas that are critical to ensure that minority and 
other underserved populations benefit equally from PGx 
advances in addiction treatment: using race variables in 
genomics research (Institute of Medicine, 2002a; 2002b) 
and ensuring equitable access to novel PGx treatments 
once they become widely available. These two issues have 
the greatest potential implications for just distribution 
of the benefits of PGx research on addiction and might 
be considered essential bookends in the examination 
of ethical issues related to the long trajectory from PGx 
research to improved health outcomes. Unless the field 
proactively addresses the ethical challenges they pose, 
innovations in addiction treatment will likely widen 
the existing disparities in treatment outcomes and the 
burden of drug dependence. 
ETHICAL ISSUES IN PHARMACOGENOMICS 
RESEARCH
Privacy and the Potential for Discrimination 
The advent of genomic medicine has raised unprec-
edented concerns about privacy and confidentiality, 
two key standards in medical research and practice that 
reflect the fundamental values of beneficence and the 
responsibility to do no harm (Beauchamp and Childress, 
2001). Genetic information is unique relative to other 
medical information in at least two respects that increase 
its sensitivity. First, information about an individual’s 
genome simultaneously provides information about his 
or her relatives (Buchanan et al., 2002; Robertson et al., 
2002; Nuffield Council of Bioethics, 2003). Second, 
many genetic variants are pleiotropic—that is, they have 
clinical relevance for more than one condition. A classic 
example of pleiotropy is a variant of the apolipoprotein 
(APOE) gene that influences both cardiac care and the 
risk of late onset Alzheimer’s disease (Hayden, 2008). 
Accordingly, some medical professionals and ethicists 
have worried that genetic research could usher in new 
forms of stigmatization and discrimination by health 
insurers or employers against individuals who are iden-
tified as having increased risk of specific conditions or 
being nonresponders to medication. 
These concerns may be amplified in the context 
of addiction. Substance abusers, especially those who 
are poor, are among the most stigmatized individu-
als in society (Room, 2005). The process of matching 
substance abusers to optimal PGx treatments could 
potentially expose them to still further devaluation, 
depending on the genetic variants used to match them to 
the optimal choice of medication. Gene variants impli-
cated in nicotine dependence, for example, have been 
associated with increased risk of becoming addicted to 
cocaine and alcohol, and with psychiatric conditions, 
including Tourette’s syndrome, post-traumatic stress 
disorder, attention-deficit hyperactivity disorder, obses-
sive-compulsive disorder, anxiety, paranoia, depression, 
and suicide (Shields et al., 2005).
Although some concerns have been allayed by the 
passage of the Genetic Information Nondiscrimination 
Act (H.R. 493, 110th Cong., 2nd Sess., 2008) and the 
Patient Protection and Affordable Care Act (H.R. 3590, 
111th Cong., 2nd Sess., 2010), many analysts still con-
sider privacy and genetic discrimination protections to 
be inadequate (Hudson et al., 2008; Slaughter, 2008; 
McGuire and Majumder, 2009). Health care reform may 
soon address concerns that individuals will be denied 
insurance coverage or charged higher premiums based 
on genetic status, but more diffuse manifestations of 
social stigma or discrimination may be harder to curtail. 
Data Storage and Use
The sensitive nature of genetic information highlights 
the need for responsible storage in biobanks and medi-
cal records and poses challenges for informed consent 
procedures (Nuffield Council of Bioethics, 2003; 
Corrigan, 2005; Peterson-Iyer, 2008). Large banks 
of genetic data are indispensable for PGx studies that 
explore how genes interact with each other and the 
environment to produce health effects, but the storage 
and use of such data raise concerns (Clayton, 2005; 
Corrigan, 2005; Haga and Burke, 2008). One chal-
lenge has been clarifying whether the scope and intent 
of participants’ informed consent for participation in 
a past study permits the use of their genetic data in 
new studies that may not have been envisioned at the 
time the consent was provided. The U.S. Department 
of Health and Human Services has advanced policy 
recommendations intended to minimize harm to and 
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respect the informed wishes of study participants while 
facilitating the aggregation of diverse data sets needed 
to advance science (U.S. Department of Health and 
Human Services, 2008). Consumers have expressed a 
preference for tiered consent schemas that allow indi-
viduals to specify the level of data sharing permitted 
with respect to their genomes (McGuire et al., 2008; 
Peterson-Iyer, 2008). 
Beyond research, as more patients undergo genetic 
testing in clinical settings, there is  growing concern about 
the storage and use of genetic test results (Buchanan 
et al., 2002; Robertson et al., 2002; Nuffield Council 
of Bioethics, 2003; Schubert, 2004; Corrigan, 2005; 
Munafo et al., 2005; Marx-Stolting, 2007; Haga and 
Burke, 2008; Henrikson et al., 2008; Peterson-Iyer, 
2008). Who should have access to individuals’ genetic 
information, and how can it be protected against unau-
thorized access, particularly as electronic health records 
(EHRs) become more widespread? The EHR concept 
aims to make relevant patient information readily avail-
able to all treating clinicians to increase the coordination 
of health care, reduce harm and waste, and increase 
quality and efficiency. 
However, the question of how much of patients’ 
genetic status data should be included in EHRs, and 
under what restrictions, has not yet been systematically 
addressed. I have argued elsewhere (Shields et al., 2005) 
that the sensitive nature of addiction-related phenotypes 
warrants increased scrutiny regarding processes for storing 
and communicating information about patients’ genetic 
status and that prudent policies should be based on the 
most potentially stigmatizing information generated by 
a given genetic test.
Answers to these questions will become increasingly 
urgent and financial incentives aimed at increasing EHR 
use within the U.S. health care system promise to accel-
erate widespread adoption of EHR systems nationally. 
(Currently only 13 percent of physicians [DesRoches 
et al., 2008] and 8 percent of hospitals (Jha et al., 2007; 
2008) have EHR systems in place.)  
Beyond the clinic, the proliferation of “home-brew” 
genetic tests (manufactured with noncommercial reagents 
and not approved by the U.S. Food and Drug Admin-
istration) (Buchanan et al., 2002) and the accumula-
tion of genetic information by private companies that 
market genetic tests directly to consumers (Wolfberg, 
2006; Hudson et al., 2007; Hogarth et al., 2008) pose 
further challenges to ensuring against irresponsible use 
of genetic test results. 
Provider Readiness to Use PGx Treatments
Although genetically guided treatment has been incorpo-
rated into routine practice in some specialties for many 
years (e.g., oncology), the fact that addiction is most 
often first treated in primary care settings will pose sub-
stantial challenges for clinical integration, with practices 
serving poor and minority patients likely to face greater 
challenges than others (Bach, 2004). Few primary care 
physicians (PCPs) have formal training in genetics, which 
constitutes a barrier to clinical integration of novel PGx 
treatment strategies. Nationally, only 4 percent of PCPs 
report feeling very prepared to counsel patients consider-
ing genetic testing, and 5 percent feel very confident in 
interpreting genetic test results (Shields et al., 2005). In 
studies addressing challenges to incorporating genetically 
tailored smoking-cessation treatment, merely describ-
ing a new test to tailor smoking-cessation treatment as 
“genetic” (vs. “nongenetic”) reduced physicians’ willing-
ness to offer it to their patients (Shields et al., 2005). 
Informing physicians that the same genotypes that likely 
would be used to match patients to optimal treatment 
were also associated with increased risk of becoming 
addicted to substances besides tobacco markedly damp-
ened their enthusiasm for testing (Levy et al., 2007).  
Understanding the genetics of complex behaviors 
such as addiction will place particular demands on phy-
sicians. Future PGx approaches to identify treatment 
responders and nonresponders will likely involve assessing 
multiple genes in multiple interacting neurobiological 
pathways that mediate a medication’s pharmacodynamic 
effects, as well as genetic variants in drug metaboliz-
ing enzymes (Munafo et al., 2005; Rutter, 2006). PGx 
practitioners will need to evaluate not only the relative 
importance of multiple gene variants, but also potential 
interactions of these polymorphisms with other drugs and 
environmental exposures. Clear and accessible guidelines 
will be essential to assist PCPs and allied health profes-
sionals with addiction treatment decisions (Freedman 
et al., 2003), as will decision support available through 
EHR systems. 
Minorities with substance dependence are more 
likely than whites to be treated in primary care settings 
rather than specialty alcohol or drug treatment programs 
(Schmidt et al., 2007). Therefore, preparing PCPs to 
implement new PGx treatments for addiction will have 
a direct bearing on disparities. To achieve this prepara-
tion, infrastructure and capacity will need strengthening. 
Small primary care practices, which currently make up 50 
percent of all practices nationally (Burt et al., 2005), are 
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especially in need of infrastructure development. They 
consistently lag behind in adoption of new technologies, 
such as health information technology (DesRoches et al., 
2008). Ensuring that PCPs have access to EHR systems 
that have the decision support platforms they need will 
be essential to guarantee that future PGx treatment 
strategies for addiction reach underserved patients in 
need of substance abuse treatment.
Patients’ Willingness to Undergo Genetic Testing
Ultimately, patients will benefit from PGx treatment 
strategies only if they are willing to undergo genetic test-
ing. Therefore, it is critical to understand how patients’ 
knowledge, attitudes, and experiences may affect their 
willingness to participate in PGx-based medicine. Several 
studies have documented a general lack of awareness, 
knowledge, and understanding of genetic testing (Blu-
man et al., 1999; Donovan and Tucker, 2000; Kinney 
et al., 2000; Singer et al., 2004), especially among low-
socioeconomic status (SES) and minority communities 
(Hughes et al., 1997; Mogilner et al., 1998; Lipkus et 
al., 1999; Kinney et al., 2001; Armstrong et al., 2002; 
Peters et al., 2004; Singer et al., 2004; Bates et al., 2005; 
Murphy et al., 2009; Suther and Kiros, 2009). Individu-
als’ interest in genetic testing rises with educational level 
(Andrykowski et al., 1996; Mogilner et al., 1998; Lerman 
et al., 1999; Peters et al., 2004), and those with higher 
levels of education express fewer concerns about possible 
misuse of genetic information (Suther and Kiros, 2009). 
Mistrust is a major factor affecting patients’ will-
ingness to undergo genetic testing, especially within 
minority communities that have historically experienced 
discrimination. Although some studies have found no 
racial differences in willingness to undergo genetic testing 
(Lacour et al., 2008), several have shown that African 
Americans are more likely than other groups to believe 
that genetic test results will be misused (Singer et al., 
2004; Suther and Kiros, 2009), be used to label their 
racial/ethnic group as inferior (Thompson et al., 2003; 
Peters et al., 2004), or lead to racial discrimination (Zim-
merman et al., 2006). African Americans are far more 
likely than other groups to see racism as a significant 
problem in health care (Lillie-Blanton et al., 2000) and 
consistently report racial discrimination in obtaining 
medical care (Henry J. Kaiser Family Foundation, 1999; 
Klassen et al., 2002; Smedley et al., 2003). The legacy of 
the Tuskegee syphilis study (Gamble, 1997) and of insur-
ance and employment discrimination based on the results 
of sickle cell screening (Bowman and Murray, 1990; 
King, 1992a; 1992b) remain salient within the African 
American community. African Americans tend to have 
negative views about participation in medical research 
and to be skeptical that their community will share in 
any positive benefits of genetic research (Corbie-Smith 
et al., 1999). Latinos also have expressed mistrust about 
genetic testing. In a national survey of 1,724 individuals, 
African Americans were 66 percent and Latinos were 
58 percent  more likely than whites to have concerns 
about potential misuse of genetic information (Suther 
and Kiros, 2009). 
Religious orientation also shapes attitudes toward 
genetic testing. Regular church attendance and reliance 
on God in health care decisionmaking correlate negatively 
with perceived benefits and acceptance of genetic testing, 
and are traits more common among African Americans 
than whites (Singer et al., 2004). Catholics are less likely 
to endorse positive views of genetic testing, and Latinos 
are more likely to be Catholic (Singer et al., 2004). In 
summary, outreach and communication strategies tai-
lored to the needs, preferences, and cultures of minority 
and low-SES communities will be necessary to ensure 
that new PGx treatment strategies for addiction are 
translated into practice in ways that improve treatment 
outcomes for all patients and do not exacerbate existing 
racial and SES disparities.
THE USE OF RACE VARIABLES IN PG x 
RESEARCH
While the majority of ethical analyses of PGx have 
focused on the ethical imperative to do no harm at the 
level of the individual patient, two key issues have par-
ticular salience for the notion of distributive justice and 
the potential of PGx research to translate into harm or 
benefit for minority communities. The first relates to how 
race variables are used, interpreted, and communicated 
in PGx research. Numerous articles and editorials have 
debated the implications of using race variables in the 
design of genetic research studies, data interpretation, 
results communication, and impact on broader soci-
etal concerns (Osborne and Feit, 1992; Bhopal, 1997; 
Kaufman and Cooper, 2001; Lee et al., 2001; Schwartz, 
2001; Wood, 2001; Burchard et al., 2003; Cooper et 
al., 2003; Haga and Venter, 2003; Kaplan and Bennett, 
2003; Stevens, 2003; Cooper, 2004; Shields et al., 2005). 
There are three major drawbacks to using self-identified 
racial variables in PGx research on addiction:
•  self-identified race is an inadequate proxy for human 
genetic heterogeneity;
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•	focus on race obscures understanding the role of envi-
ronmental influences; and
•	the	use	of	race	variables	increases	the	potential	for	
discrimination.
Race Versus Genetic Heterogeneity
Racial categories mask genetic diversity, so that PGx 
treatments based on research using racial categories could 
be ineffective or even harmful for many individuals. 
Self-identified racial categories such as those set forth by 
the Office of Management and Budget (OMB Directive 
15, National Institutes of Health, 2001) and used in the 
federal census are a rough and poorly characterized proxy 
for defining an amalgam of influences related to social 
identity, geographical ancestry, and social status (Shields 
et al., 2005). More scientifically precise methods are 
available for measuring population structure (Novembre 
et al., 2008; Bryc et al., 2010) and should be used.
The limited usefulness of self-identified racial cat-
egories is perhaps most clearly illustrated by the term 
“African American,” since genetic heterogeneity is greater 
among self-identified African Americans than among 
most other self-identified groups. For example, Bryc 
and colleagues (2010) analyzed fine-scale population 
structure among 146 individuals representing 11 dif-
ferent populations in West and South Africa; 57 Yor-
ubas genotyped as part of the International HapMap 
project; 365 self-identified African Americans from 
throughout the U.S.; and 400 individuals in Europe. 
The researchers used fine-scale genetic mapping to infer 
the mix of African ancestries in the African Americans 
and to identify West African populations closest to the 
ancestral populations of African Americans. Although 
the African Americans as a group averaged 77 percent 
West African ancestry, individual African Americans 
ranged from less than 1 percent to more than 99 percent 
West African ancestry (Figure 1; Bryc et al., 2010). Such 
diversity compels extreme caution in prescribing clini-
cal guidelines or developing warnings for adverse drug 
responses for “African Americans.” 
Fine-scale mapping of European cohorts has identi-
fied genetically distinct subpopulations (Lao et al., 2008; 
Novembre et al., 2008; McEvoy et al., 2009) that would 
be missed if the general terms “European” or “white” were 
used in analyses. For example, using genotype data from 
197,146 loci from 1,387 individuals of European ances-
try from the Population Reference Sample, Novembre 
and colleagues (2008) were able to identify genetically 
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FIGURE 1. African and European Ancestry in African Americans
A representative individual among 365 self-identified African Americans had 73.5 percent West African ancestry, as revealed by genomic 
analysis (A). West African ancestry ranged from less than 1 percent in one individual (B) to over 99 percent. Blue bands = West African 
ancestry in both maternal and paternal chromosomes; green = West African ancestry in one chromosome and European ancestry in the 
other; red = European ancestry in both maternal and paternal chromosomes.
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distinct subpopulations among French-, German-, and 
Italian-speaking groups in Switzerland.
With new technologies (e.g., the Affymetrix 500k 
SNP chip) now widely available to identify nuanced dif-
ferences in population structure, the use of gross racial/
ethnic categories in PGx studies or treatment guidelines 
becomes ethically problematic. Although technical limi-
tations or resource constraints sometimes will limit a 
research team’s ability to do such fine-scale mapping, 
its availability raises the bar for all genomics researchers. 
Race, Genes, and Environmental Exposures 
The use of self-identified race as a proxy for human 
genetic heterogeneity in PGx studies of addiction is 
especially problematic when studies do not measure 
other social and physical environmental exposures that 
track with race in America. First, such analyses increase 
the likelihood that the self-identified race variable will be 
statistically significant and thus reify self-identified race 
as the most relevant frame for understanding differences 
in response to addiction treatment. Second, such research 
designs miss the opportunity to disentangle complex 
genetic, social, and environmental interactions (Hernan-
dez and Blazer, 2006) or epigenetic effects (Olden et al., 
2011) that affect the progression to addiction, response 
to treatment, or a drug’s kinetic effects.
Potential for Worsening Discrimination
The poor specificity of racial/ethnic variables in PGx 
research is often compounded by failure to measure 
social and environmental exposures that track with self-
identified race in America, thereby masking important 
gene-environment effects. Missing these effects means 
missing an opportunity to disentangle the complex 
social, environmental, behavioral, and genetic factors 
that interact to create disease and determine treatment 
outcomes. PGx studies of addiction would likely be far 
more informative if population structures were finely 
mapped and if other social and environmental exposures 
that often track with “race” were measured indepen-
dently. Such research would also be more likely to yield 
insights useful for addressing disparities. Low-SES and 
minority patients’ experiences subject them to a distinct 
confluence of social and environmental exposures that 
likely interact with clinically relevant genotypes.
PGx analyses that frame new knowledge in terms 
of “racial differences” in allele frequencies relevant to 
disease risk or drug response continue a long and painful 
history of comparative racial science in the U.S. Such 
science leads to headlines such as “Blacks more likely to 
have gene X associated with addiction,” and has almost 
always been used to allege that African Americans are 
inferior (King, 1992a; 1992b). When “racial” differences 
intersect with socially charged phenotypes, such as those 
related to addiction or mental illness, physicians shy 
away from genetic testing for fear that results may lead to 
discrimination against their patients (Levy et al., 2007). 
The reporting of higher frequencies of genotypes 
associated with addiction to nicotine, cocaine, and other 
substances among African Americans relative to whites 
has a particularly problematic intersection with exist-
ing racial stereotypes. For example, several studies have 
documented physicians’ inadequate prescribing of pain 
medications for African American patients relative to 
white patients with similar conditions and illness severity, 
noting physician concerns about potential drug abuse 
by minority patients (Cleeland et al., 1997; Todd et al., 
2000). It is not surprising, therefore, that African Ameri-
cans tend to be more concerned than other groups that 
genetic test results will be used to discriminate against 
them or their community. 
ACCESS TO NOVEL PGx ADDICTION  
TREATMENTS 
The second “bookend” of the PGx research trajectory 
that has important implications for distributive justice 
is ensuring equal access to new PGx applications once 
they are validated and available to be used in clinical 
settings. To the extent that novel PGx treatments for 
addiction improve outcomes by an order of magnitude 
over previous regimens, it will be especially important 
to ensure equal access to these markedly improved treat-
ments; otherwise, these advances will merely widen the 
existing disparities gap in substance abuse treatment. 
Disparate access to new technologies and treatments 
is certainly not a new issue; widespread and persistent 
gaps have been documented (Smedley et al., 2003). 
A successful strategy for ensuring equal access to PGx 
information and treatments must engage patients, pro-
viders, and policymakers. The benefits of individual-
ized treatment must be communicated to minority and 
low- SES patients in ways that are culturally competent, 
accessible, and appropriate, and that mitigate concerns 
about genetic testing (Betancourt, 2004). Modes of 
dissemination must be carefully considered. The recent 
Health Information National Trends Survey indicated 
that media saturation on a given topic reaches similar 
percentages of people in all socioeconomic position 
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(SEP) classifications; in the absence of media saturation, 
however, people in higher SEP groups have better access 
to other sources of information, such as physicians or 
informed friends (Viswanath et al., 2006). Diffusing 
information about genomic medicine is challenging in 
any context. Even with the establishment of high-risk 
guidelines for hereditary breast and ovarian cancer in the 
1990s (American Society of Clinical Oncology, 1996; 
Daly, 1999) and the development of BRCA1/2 testing 
to assess hereditary breast cancer risk, only 10.7 percent 
of women who were appropriate candidates for genetic 
testing according to national guidelines had ever even 
discussed the possibility of genetic testing with their 
doctor or another health professional (Levy et al., 2009).
Ensuring that new PGx treatments reach minority 
and low-SES patients will require investment in the 
infrastructure and clinical capacity of the providers who 
serve them. One potential strategy for reaching minority 
patients is to concentrate on minority-serving providers. 
Approximately 22 percent of physicians, for instance, care 
for 80 percent of all black Medicare beneficiaries in the 
U.S. (Bach et al., 2004). Focusing on minority-serving 
providers may be an especially effective strategy in the 
context of substance abuse treatment, given that minori-
ties with substance dependence are more likely than 
whites to be treated in primary care settings rather than 
specialty alcohol or drug treatment programs (Schmidt 
et al., 2007). 
The challenges related to physicians’ preparedness 
to incorporate PGx treatments into practice will be 
especially keen in these settings that disproportionately  
serve poor and minority patients. In a national survey 
of PCPs, those who served the highest proportions of 
minority patients (i.e., ranking in the top 20 percent of 
the national distribution) were significantly less likely to 
have ever ordered a genetic test to assess risk for breast 
cancer (18 percent vs. 29 percent; P = 0.01), colon cancer 
(11 percent vs. 18 percent, P = 0.05), or Huntington 
disease (6 percent vs. 18 percent; P < 0.001) compared 
with those serving fewer minority patients (Shields et 
al., 2008). Among community health centers (CHCs), 
which serve 1 in 4 poor, 1 in 7 uninsured, and 1 in 10 
minority patients (National Association of Community 
Health Centers, 2005), only 4.3 percent have the capacity 
to deliver genomics services (Shields et al., unpublished 
data). These findings are consistent with several studies 
documenting safety net providers’ difficulty accessing 
specialty care for their patients (Felt-Lisk et al., 2002; 
Felland et al., 2003).
Targeted financial support is also likely to be needed. 
The current average CHC operating margin is less than 
1 percent (McAlearney, 2002; National Association 
of Community Health Centers, 2005), leaving scarce 
resources to expand genetics services. Safety net hospitals 
and clinics that disproportionately serve minority patients 
are similarly strapped (Lewin and Altman, 2000; Varkey 
et al., 2009). Increased fiscal pressures have decimated 
many state Medicaid programs, the primary source of 
health insurance for low-income families, and many of 
these programs have restricted prescription drug benefits 
(Crowley et al., 2005; Kaiser Commission on Medicaid 
and the Uninsured, 2010). Low-income Americans will 
not have equal access to PGx treatments if Medicaid 
does not provide the same coverage for these services 
as private insurers.
The over-representation of minorities dependent 
on substances among the uninsured also threatens 
to exacerbate disparities. According to data from the 
National Alcohol Survey, for example, 28 percent of 
African Americans and 41 percent of Hispanics with a 
current substance dependence diagnosis are uninsured, 
compared with only 19 percent of whites with such a 
diagnosis (Schmidt and Mulia, 2009). Uninsured adults 
have tremendous difficulty accessing care for alcohol, 
drug abuse, and mental health problems (Wells et al., 
2002). Uninsured adults and those on Medicaid have 
the greatest unmet need and delays in care (Wells et 
al., 2002). While health care reform may reduce some 
of these barriers, many will surely remain. Targeted 
supplemental reimbursement will most likely be needed 
to enable safety net providers to ensure access to new 
PGx treatments for addiction.
CONCLUSION
PGx research is making remarkable progress in iden-
tifying genetic variants associated with increased vul-
nerability to drug dependence and variable response 
to substance abuse treatment. The next generation of 
studies, now just beginning, will tackle measurement of 
gene-gene and gene-environment interactions that affect 
susceptibility and treatment responses. The sensitive and 
stigmatized nature of addiction phenotypes, in concert 
with pleiotropic associations of key genotypes with other 
socially stigmatized conditions, warrants great care in 
the handling of reporting and use of PGx test results. 
It is hard to overstate the importance of finding ways 
to communicate the complex and continuous nature 
of human genetic variation to the general public and 
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Traditional racial categories are ill-suited to pharmacogenomics (PGx) research, especially in studies that examine sensitive phenotypes such 
as drug abuse and addiction. From this viewpoint, I assessed the use of race variables in all 2007–2010 PGx addiction publications included in 
a recent comprehensive review conducted by Mroziewicz and Tyndale (2010).
All 32 human studies used self-reported race/ethnicity variables for participant recruitment. Two required a more stringent self-reported defini-
tion: Berrettini and colleagues (2008) enrolled only participants “for whom the four grandparents were of European origin,” and Le Marchand 
and colleagues (2008) enrolled only those “having both parents of Japanese or European ethnicity, or of any amount of Native Hawaiian  
ancestry.” 
The thorny issues related to successfully recruiting a diverse study population and resolving the tensions between self-identified race and 
population structure have led many researchers to sidestep the issue completely by studying only “European” or other samples assumed to 
be genetically homogeneous. Eighteen of the 32 studies took this route by recruiting all participants from “single” populations. Ten studies 
included only “European” or “Caucasian” subjects, with no further information given (Audrain-McGovern et al., 2007; Bierut et al., 2007; Lee, 
et al., 2007; Vanyukovet al., 2007; Amoset al., 2008; Berrettini et al., 2008; Conti et al., 2008; Uhl et al., 2008; Oroszi et al., 2009; Pillai et al., 
2009). Six other studies were conducted with “Europeans” or “Caucasians” from specified locations (e.g., Northern Poland [Sieminska,et al., 
2008]; Croatia [Mokrovic et al., 2008]; and Finland [Arias et al., 2008]); and persons of “European descent” from St. Louis, Detroit, Minneapo-
lis, and Australia (Saccone et al., 2007). Other “single” population studies included Koreans (Kim et al., 2009) and Han Chinese from Taiwan 
(Huang et al., 2007). The most common rationale provided for limiting analyses to a “single” population was to “minimize the potential bias 
resulting from ethnic admixture” (Audrain-McGovern et al., 2007; Huang et al., 2007; Lee et al., 2007; Amos et al., 2008; Berrettini et al., 2008; 
Conti et al., 2008; Hung et al., 2008; Lerman et al., 2010). 
Of the 32 studies in our sample, only seven (one multiethnic and six “single” population) conducted additional analyses to assess population 
structure and admixture using ancestry-informative markers (AIMs). For example, a multi-ethnic study used 207 AIMs to “verify self-reported 
ancestry and assess admixture within racial groups,” using an inclusion threshold of at least 80 percent ethnic identity (Sherva et al., 2008). 
Saccone and colleagues (2007) similarly analyzed “289 high performance” single nucleotide polymorphisms (SNPs) to test for population 
admixture among their “European” cohort of participants from St. Louis, Detroit, Minneapolis, and Australia, but found no evidence of popu-
lation structure. In all these cases, if the investigators found no evidence of population structure using AIMs, they assumed there was none. 
These results, however, contrast dramatically with the fine-scale mapping of Europeans by Novembre and colleagues (2008) that found identi-
fiable population structure within very narrow geographical areas, emphasizing the high threshold for identifying population structure embed-
ded in the STRUCTURE software program typically used. AIMs are only as robust as the reference population samples used to identify a set of 
given SNPs as indicative of membership in one ancestral group versus another. Using Yorubas to stand in for all persons of African ancestry 
(Tishkoff et al., 2009; Bryc et al., 2009) is faulty from the start, as recent research has shown. 
These research practices have important ramifications for determining who will benefit from PGx research on addiction. First, the extent to 
which PGx study results are generalizable to all persons of “European” ancestry is questionable, let alone persons of more distant geographi-
cal heritage. What genetic effects might reach the threshold of significance if populations were defined with greater specificity and studies 
were adequately powered to capture genetic effects among these identifiable subpopulations? An important challenge for PGx research will be 
to determine which levels of genetic heterogeneity are important to measure for clinical purposes, a calculation that may differ according to 
phenotype. In the case of PGx research, the importance of identifying individuals at risk of adverse drug events, and the consequences of not 
identifying such individuals, demands a more fine-grained approach to defining clinically relevant subpopulations than is typically used in cur-
rent practice. 
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to discover new ways of framing genetic information 
about differential risk of illness or response to treatment 
in ways that transcend the very harmful blunt instru-
ment of traditional racial/ethnic categories. While these 
categories continue to be a useful bureaucratic tool for 
tracking health disparities, they are no longer appropriate 
for use in biomedical research aimed at understanding 
the etiology of complex diseases such as addiction or 
factors affecting treatment response. 
There is great hope that PGx research will change the 
landscape of addiction in America by enabling physi-
cians to match individual patients to the substance abuse 
treatment that will work best for them based on their 
genetic profile and other information. For this to happen, 
however, patients must be willing to undergo genetic 
assessment, physicians must have the capacity and will-
ingness to refer their patients for genetic assessment and 
execute the tailoring of treatment recommendations, and 
health insurers must be willing to cover the costs of such 
services. The more effective PGx treatment strategies are 40 • ADDICTION SCIENCE & CLINICAL PRACTICE—JULY 2011
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relative to current strategies, the more important it will 
be to ensure that minority and underserved populations 
are able to access them. Otherwise, PGx treatments for 
addiction will exacerbate already dramatic disparities in 
the burden of addiction and its impact on individuals’ 
and families’ health and horizons of opportunity.
Ensuring that research designs are adequately pow-
ered to identify clinically relevant subpopulations in 
terms of both genetic structure and environmental expo-
sures will be essential to maximizing the benefits and 
minimizing the harms of PGx research. At the other 
end of the translational spectrum, once efficacious new 
treatment strategies for addiction are ready for wide-
spread use, the challenge will be to find creative ways to 
overcome the disparities in access and quality of care that 
have forever plagued our health care system. Addiction 
is a debilitating disease and one that affects not only 
individuals, but also families and generations to come. 
Commitment to reaching those communities in greatest 
need with improved treatments for addiction could go 
a long way toward addressing these disparities.
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